What is Antiverse?
Antiverse operates at the intersection of artificial intelligence and life sciences, focusing on the development of next-generation computational antibody design technology. The company's core mission is to facilitate the discovery of therapeutic candidates for challenging drug targets, including G-protein coupled receptors and ion channels. By integrating machine learning with structural biology, Antiverse aims to reduce the time and cost associated with traditional drug development, providing a scalable solution for pharmaceutical partners seeking to address unmet medical needs. Its market position is defined by its ability to bridge the gap between complex biological data and actionable therapeutic insights, making it a key player in the evolving digital health ecosystem.
How much funding has Antiverse raised?
Antiverse has raised a total of $18.9M across 4 funding rounds:
Angel/Seed
$2M
Other Financing Round
$3M
Angel/Seed
$4.6M
Series A
$9.3M
Angel/Seed (2021): $2M with participation from Syndicate Room, The Cambridge Angels, Angel Co-Investment Fund, Wren Capital, Ed Parkinson, Development Bank of Wales, and Tensor Ventures
Other Financing Round (2023): $3M led by AngelHub, Deep Science Ventures, Tensor Ventures, and Innospark Ventures
Angel/Seed (2024): $4.6M supported by AngelHub, Kadmos Capital, Tensor Ventures, i&i Biotech Fund, and Innospark Ventures
Series A (2026): $9.3M featuring Kadmos Capital, Development Bank of Wales, Soulmates Ventures, and Innovative Investments Capital Funding Group
Key Investors in Antiverse
Tensor Ventures
A next-generation venture capital firm specializing in combinatorial technologies, including AI, Quantum Technology, and Computational Biotech, with a focus on disruptive deep-tech startups.
Innospark Ventures
An investment firm dedicated to supporting founders who utilize Artificial Intelligence to solve complex challenges in healthcare, life sciences, and enterprise sectors.
i&i Biotech Fund
A specialized European early-stage biotech venture capital fund that supports innovative life sciences startups focused on drug discovery, diagnostics, and AI-driven medical solutions.
What's next for Antiverse?
With the successful closure of this Series A round, Antiverse is well-positioned to transition from a research-focused entity to a commercial-stage powerhouse. The strategic roadmap likely includes the expansion of its internal pipeline of antibody candidates and the strengthening of its collaborative partnerships with global pharmaceutical leaders. As the company scales, the focus will shift toward validating its computational models through clinical-grade data and optimizing its platform for broader therapeutic applications. Investors will be closely monitoring the firm's ability to translate its design capabilities into tangible clinical assets, which will be the primary driver for future valuation growth and potential exit opportunities in the high-stakes biotech sector.
See full Antiverse company page
